• Biotechnology Industry Report 2015

    The biotech sector reached new heights in 2014, setting records in key financial metrics and achieving several high-profile product breakthroughs and scientific advancements.

  • How 'fit' is your capital allocation strategy?

    Biopharma management teams and boards of directors should proactively assess the “fitness” of their capital allocation strategies and exercise their inner activists to improve long-term value.

  • Financial reporting briefs - life sciences

    This edition highlights the latest developments in financial reporting for Q4 2014 including highlights from the AICPA National conference, accounting updates and regulatory developments.

  • Pharmaceutical R&D tax incentives

    Globalization of the pharmaceutical industry and increased outsourcing have drastically changed the R&D landscape. This report explores the impact on R&D tax incentives.

  • Global Corporate Divestment Study

    Are you considering divesting assets? If not, you should be. Our global study explains why and highlights the strategies to increase speed and value.

  • Megatrends - Health reimagined

    Health care is embarking on a once-in-a-lifetime transformation. This report explores what the industry needs to do to achieve future success.

  • Firepower and growth gap report 2015

    Biopharma M&A reached record levels in 2014, with firms seeking focus, scale and growth. Read more about last year’s deal-making landscape in our 2015 outlook.

  • Navigating the payer landscape

    A revolution is happening in health care, and it’s being led by payers. Progressions, our global pharmaceutical report, explores how companies are responding.

  • Firepower fireworks drive record biopharma M&A in 2014

    As the dust settled in the waning days of the year’s end, EY took stock of the biopharma deals consummated in 2014 to understand the implications for the year ahead.

Life Sciences

Finding sustainability in biotechnology, pharmaceutical and medical technology

Amplified business decisions are the new norm thanks to rapid changes. From new market entrants and regulatory reform to expiring patents and the growing challenge of chronic diseases, leaders in the life sciences community must explore a new course to address the changing climate for health care — one driven by patients and focused on health outcomes.

Our Global Life Sciences Center brings together a worldwide team of professionals to help you achieve your potential.

We cover key issues in these areas:




Connect with us

Stay connected with us through social media, email alerts or webcasts. Or download our EY Insights app for mobile devices.

EY Webcast: Revenue recognition standard for life sciences companies.

EY -  Webcast: Revenue recognition standard for life sciences companies.

Join us on 15 June for a discussion on the implications of the new revenue recognition standard for life sciences companies and how companies should plan for implementation.

Megatrends - Health reimagined

EY - Megatrends - Health reimagined

Health care is embarking on a once-in-a-lifetime transformation. This report explores what the industry needs to do to achieve future success.